Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,264,896
  • Shares Outstanding, K 1,293,620
  • Annual Sales, $ 26,107 M
  • Annual Income, $ 4,628 M
  • 36-Month Beta 1.01
  • Price/Sales 3.51
  • Price/Cash Flow 7.32
  • Price/Book 3.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.63
  • Number of Estimates 8
  • High Estimate 2.04
  • Low Estimate 1.34
  • Prior Year 1.60
  • Growth Rate Est. (year over year) +1.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.50 +6.09%
on 10/26/18
76.44 -7.71%
on 10/16/18
-3.04 (-4.13%)
since 10/12/18
3-Month
66.50 +6.09%
on 10/26/18
79.61 -11.38%
on 10/03/18
-6.76 (-8.74%)
since 08/14/18
52-Week
64.27 +9.77%
on 05/03/18
89.54 -21.21%
on 01/29/18
-0.60 (-0.84%)
since 11/14/17

Most Recent Stories

More News
Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges

With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.

COCP : 2.73 (+1.11%)
ZIOP : 2.70 (unch)
GILD : 70.55 (-0.52%)
REGN : 337.29 (-1.41%)
SNY : 45.08 (+0.40%)
Roche's Tecentriq Gets Priority Review for Breast Cancer

Roche's efforts to expand the label of its immuno-oncology drug Tecentriq advances as the FDA accepts its sBLA and grants priority review for the treatment of breast cancer.

NVS : 87.33 (-1.11%)
GILD : 70.55 (-0.52%)
RHHBY : 30.8700 (-0.74%)
AMGN : 190.36 (-0.62%)
Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down

Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.

GHDX : 75.76 (-2.75%)
AMRN : 16.12 (+4.81%)
GILD : 70.55 (-0.52%)
ALXN : 116.11 (-2.03%)
Cronos (CRON) to Report Q3 Earnings: What's in the Offing?

Cronos' (CRON) third-quarter results are likely benefit from the company's collaboration initiatives to become one of the most promising cannabis company.

CRON : 8.12 (-2.29%)
TLRY : 102.34 (-8.26%)
GILD : 70.55 (-0.52%)
BMY : 52.59 (unch)
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.

TLRY : 102.34 (-8.26%)
NVS : 87.33 (-1.11%)
GILD : 70.55 (-0.52%)
BMY : 52.59 (unch)
Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L. Washington, Gilead's Executive Vice President and Chief Financial Officer, and John McHutchison, AO, MD, Gilead's Chief...

GILD : 70.55 (-0.52%)
After Yesterday's Decline of 1.04%, Gilead Sciences Offers Investors Better Value

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $70.29 to a high of $71.47. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $70.36...

GILD : 70.55 (-0.52%)
Medicines Company (MDCO) Q3 Loss Widens, Inclisiran in Focus

The Medicines Company (MDCO) suffers a wider-than-expected loss in Q3. At the same time, the company posts negative revenues.

MDCO : 20.80 (-8.77%)
ALNY : 65.07 (-3.33%)
GILD : 70.55 (-0.52%)
ALXN : 116.11 (-2.03%)
Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat

Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.

ENDP : 12.91 (-4.51%)
MRK : 74.09 (-0.70%)
GILD : 70.55 (-0.52%)
BMY : 52.59 (unch)
Arena Pharmaceuticals (ARNA) Beats on Q3 Earnings and Sales

Arena Pharmaceuticals (ARNA) betters loss estimates in Q3. Also, the top line surpasses the consensus mark.

SBPH : 10.01 (-1.57%)
ARNA : 32.52 (-3.33%)
GILD : 70.55 (-0.52%)
ALXN : 116.11 (-2.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 72.36
1st Resistance Point 71.46
Last Price 70.55
1st Support Level 69.90
2nd Support Level 69.24

See More

52-Week High 89.54
Fibonacci 61.8% 79.89
Fibonacci 50% 76.90
Fibonacci 38.2% 73.92
Last Price 70.55
52-Week Low 64.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar